Noliprel bi kuhikuhi no ka hoʻohana '

• Lapaʻau lāʻau
• Nā hōʻailona no ka hoʻohana ʻana
• Ke ʻano o ka noi
• Nā hopena hopena
• Nā Hoʻohui
• Kahawai
• Hoʻopili pū me nā lāʻau ʻē aʻe
• Ke keu
• Nā kūlana mālama
• E hoʻokuʻu i ke ʻano
• Hōʻike

Noliprel Bi-forte ka hui pū ʻana o kahi ACE inhibitor perindopril arginine a me kahi diuretic indapamide sulfonamide. ʻO ka hopena pharmacological o ka lāʻau lapaʻau ma muli o nā waiwai o kēlā me kēia kumuhana (perindopril a me ka indapamide) a me kā lākou hoʻohui synergism.
ʻO Perindopril kahi mea hoʻoweliweli ACE. Ua hoʻohuli ʻo ACE angiotensin I i ka angiotensin II (he mea make vasoconstrictor), hoʻohui ka mea hoʻonaninani i ka ʻilio aldosterone e ka cortex adrenal a me ka uha ʻana o ka bradykinin (he mea make vasodilating) i ka heptapeptides hana ʻole.
ʻO Indapam kahi huaʻawa o nā sulfonamides me kahi apo indole, pharmacologically pili i thiazide diuretics, hana e ka pale ʻana i ka sodium reabsorption i ka māhele cortical o nā keiki. Hoʻonui kēia i ka excretion o ka sodium a me nā chlorides i loko o ka urine a, ma kahi liʻiliʻi, kāohi a me ka magnesium, no laila e hoʻonui nei i ka urination a hāʻawi i kahi hopena antihypertensive.
Hōʻanoʻike o ka hana antihypertensive.
Noliprel Bi-forte ho'ēmi i ka systolic a me ka diastolic i ke koko i loko o nā mea maʻi me ka hypertension o kekahi makahiki, ma kahi o ke kuʻina a i ke kūlana kū. ʻO ka hopena antihypertensive o ka lāʻau lapaʻau ke hilinaʻi-dosis.
Loaʻa ka hopena maikaʻi loa o ka hōʻemi ʻana i ka mokulele maʻamau ventricular hema me 8 mg perindopril (like me 10 mg perindopril arginine) + 2.5 mg indapamide.
Ua emi iki ka neʻe ʻana o ke koko i ka hui perindopril / indapamide: ʻo ka ʻokoʻa ma ka hoʻemi ʻana o ka hoʻemi hoʻēmi ʻana ma waena o nā pūʻulu ʻelua o nā maʻi ʻo -5.8 mm Hg no ka pakanā systolic. ʻAniā. (95% CI (–7.9, –3.7), p 15 mg / L (> 135 μmol / L) i nā kāne a me> 12 mg / L (> 110 μmol / L) i nā wahine.
ʻO nā hui kūlike i ka Iodine. I ka hihia o ka dehydration i hoʻopili ʻia me ka hoʻohana ʻana o diuretics, piʻi ka nui o ka hoʻoulu ʻana o ka maʻi renal maʻamau, ʻoi aku ka nui o ka hoʻohana ʻana i nā ʻaina iodine e loaʻa i nā dosis kiʻekiʻe. Pono e hoʻihoʻi i ka kaulike o ka wai ma mua o ke kohoʻana i nā mea kūlike iodine.
ʻO nā paʻakai kaleka. Hiki mai paha ʻo Hypercalcemia ma muli o ke kahe ʻana o ka excretion calcium urinary.
Cyclosporin. Hiki iā ia ke hoʻonui i nā pae creatinine i loko o ke kaila koko me ka ʻole o ka hoʻopiʻi ʻana i ka pae o ka cyclosporin hūnā, a hiki i ka waʻa o ka wai a me ka hapa sela.

Ke keu

Ma kahi o kahi overdose, ʻo ka hopena maʻamau ka nui o ka hypotension arterial, i kekahi manawa hiki ke hele pū me ka mualua, ka luaʻi ʻana, ka hoʻopaʻi ʻana, ka dizziness, ka hiamoe, nā hūnā, nā oliguria, kahi e hiki ai ke holomua i ka anuria (ma muli o hypovolemia), ka haunaele. ʻO ka palaki o ka paila o ka wai-electrolyte (he hōʻemi i ka pae o ka pāhana a me ka sodium i loko o ke kaila koko), mea hoʻoluhi renal, hyperventilation, tachycardia, palpitations puʻuwai (palpitation), bradycardia, hopohopo, a me ka wāwau e hele mai paha.
Hoʻokomo mua ke kōkua mua i ka hoʻoiho wikiwiki ʻana i ka lāʻau mai ke kino: ka gastric lavage a me / a i ʻole ke koho ʻia o ke kumu hoʻopala i hoʻāla ʻia, ma hope o ka hoʻokaʻawale ʻana o ke kaulike wai-electrolyte i loko o kahi haukapila.
I ka loaʻa ʻana o kahi hypotension koʻikoʻi, pono e hāʻawi ka mea maʻi i kahi kūlana me ka pale haʻahaʻa. Inā kūpono, ʻo ke kaʻina hoʻonaʻauao ʻo ka isotonic sodium chloride e lawe ʻia ʻia a i ʻole kekahi ʻano ala ʻē aʻe e hoʻihoʻi i ka nui o ke koko.
ʻO Perindoprilat, ke ʻano hana o perindopril, hiki ke hoʻoneʻe ʻia mai ke kino e ka hemodialysis (e nānā i ka Pharmacokinetics).

He aha nā mea e pono ai nā mea kūʻai e ʻike e pili ana i ka lāʻau lapaʻau?

ʻO ka hoʻonohonohoʻana o nā papa ma kahi hoʻopihapiha e hoʻopili i ka molihue lactose lactose. Hoʻohana pinepine ʻia kēia mea no ka hoʻouka ʻana o nā ʻano lāʻau like ʻole.

ʻOiai kona waiwai kūlohelohe a me nā mea kūlohelohe, lactose ka ikaika ikaika loa. No ka poʻe e ʻeha nei i ka hoʻomehana ʻole ʻana o ka waiū waiū, nā mea aʻoaʻo no ka hoʻohana ʻana i ka lawe ʻana i ka lāʻau.

Eia kekahi, nā mea maʻi e pili pono ana i ka papaʻai ikaika e kaawale ʻole i ka paʻakai, pono e hoʻohana ʻia ka lāʻau lapaʻau me ka mālama nui loa. ʻO ka lawe ʻana i nā paila ke alakaʻi i kahi kahe o ke kahe o ke koko. Eia nō naʻe, inā ua hanana kēia ma hope o ka noi mua ʻana, a laila paha ke kumu ke hewa hewa.

Hoʻokomo ʻia kahi hana koʻikoʻi e ka pono kō o ka wai. ʻAʻole pono ʻoe e hoʻonui i ka nui o ka wai, akā i ka mahana wela ʻoi aku ka maikaʻi o ka inu ʻana i 25 pakeneka ma mua o ka mea maʻamau. ʻO ka hoʻonui hoʻonui ʻana i ka hui me ka lālani hiki ke alakaʻi i ka dehydration.

Nā hopena hopena

ʻO kahi lāʻau lapaʻau i kauoha ʻia e ka loea e alakaʻi i nā hopena maikaʻi ʻole i kekahi poʻe. ʻO Noliprel A Be Forte, nā loiloi e hōʻoiaʻiʻo i kēia ʻikepili, hiki ke hōʻia i nā hopena ʻaoʻao.

Palani 3. Nā hopena pili kūpono

Pūnaehana pīhoihoi waena	Pono, hopohopo, haunaele hiamoe, etc.
ʻŌnaehana Genitourinary	Hoʻonui i ka diuresis, hoʻoemi i ka libido, i hoʻemi i potency, etc.
Allergic hopena pili	Anaphylactic shock, urticaria, eczema, angioedema, etc.
Nā ʻōpū hanu	Pneumonia, maloʻo maloʻo, rhinitis a me nā mea hou aku.
ʻŌpala Gastrointestinal	Nausea, luaʻi, ʻeha, ka maʻi hepatitis, etc.
Nā hui ʻōpū	Hoʻopau i nā tinnitus, nā ʻono o ka metala, a me nā mea hou aku.
ʻO kekahi	Ka huluhulu iawe loa.

ʻOkoʻa paha nā hopena ʻokoʻa mai nā mea i hōʻike ʻia i ka papaʻaina. Hiki ke loaʻa ka papa inoa piha i nā ʻōlelo i hoʻohana ʻia.

Ma hope o ka kūkākūkā ʻana me Dr. Noliprel AB Forte, kahi hoʻohālikelike o ka maʻalahi maʻalahi e kūʻai aku ma kekahi mau lāʻau lapaʻau, hiki iā ʻoe ke hoʻololi me ka:

• Indapamide + Perindopril,
• Ko-Perineva,
• Noliprel (A, A Bi, A Forte), etc.

Nā Nao Koi Noliprel Be Forte i like nā like / like a me ka hopena. Eia nō naʻe, ʻokoʻa ka loli a me ka uku.

Hiki i nā ʻike e pili ana i nā kumu kumu o ke koko kiʻekiʻe e ʻike ʻia ma ka wikiō aʻe:

E hoʻokuʻu i ke ʻano a me ka ʻano

Hoʻokuʻu ʻia kahi lāʻau lapaʻa ma ke ʻano o nā papa ʻoniʻoni kiʻi film: biconvex, pōʻai, keʻokeʻo (29 a 30 paha i kēlā me kēia ma ke kumukūʻai polypropylene i hoʻolako ʻia me kahi dispenser a me kahi kīmi i loaʻa i nā kohu wai kulu, 1 pahu i loko o kahi pahu pahu me kahi hoʻokele mua mua, no nā haukapila - 30 mau pcs i loko o ka hue polypropylene me kahi mea he dispenser, 3 mau bole i kahi pahu pepa me kahi mana e wehe mua ai, 30 mau pahu i kahi pali, kahi pahu pahu me kahi pihi mua mua o ka pallet a me nā kauoha no ka hoʻohana ʻana iā Noliprel A Bi-f waha).

Helu 1 papa:

• mau mea ikaika: perindopril arginine - 10 mg (e like me ka perindopril ma ka nui o ka 6.79 mg), indapamide - 2,5 mg,
• Nā kumuhana hou: anhydrous colloidal silicon dioxide, magnesium stearate, lactose monohala, maltodextrin, sodium carboxymethyl starch (type A),
• uhiʻa kiʻi ʻoniʻoni: magnesium stearate, macrogol 6000, titanium dioxide (E171), hypromellose, glycerol.

Ka hana lāʻau lapaʻau

ʻO NOLIPREL BI-FORTE ka hui ʻana o ʻelua mau mea ikaika, perindopril a me indapamide. ʻO kēia kahi lāʻau lapaʻau hypotensive, hoʻohana ʻia e mālama i ke koko kiʻekiʻe (hypertension). Wehewehe a NOLIPREL BI-FORTE i ka poʻe maʻi i lawe ʻē aʻe i ka perindopril 0 mg a me ka indapamide 2.5 mg i kahi kaʻawale. Ka mea, hiki i nā mea maʻi ke lawe i kahi papa NOLIPREL BI-FORTE, aia kahi o kēia mau mea ʻelua.

Nā hōʻailona no ka hoʻohana ʻana

Aia ʻo Perindopril i kahi papa o nā lāʻau lapaʻau i kapa ʻia ʻo ACE inhibitors. Pēlā ia ma o ka hoʻopio ʻana i kahi hopena hoʻonui ma ke kīʻaha koko, e hōʻoluʻolu i ka hoʻonāuki ʻia o ke koko. He diuretic ʻo Indapamide. Hoʻonui ka diuretics i ka nui o nā urine i hana ʻia e nā keiki. Eia naʻe, ʻokoʻa ka indapamide ʻokoʻa i nā diuretics ʻē aʻe, me ka mea e hoʻonui iki wale ai i ka nui o nā urine i hana ʻia. E hoʻohaʻahaʻa i kēlā me kēia mea i ka hoʻokahe koko a ʻike pū ʻia lākou i ke kaʻe o ke koko.

Nā Hoʻohui

- inā he maʻi maʻamau ʻoe i ka perindopril, kekahi mea paʻa o ka ACE, indapamide, kekahi o ka sulfonylamides a i ʻole kekahi mea ʻē aʻe o NOLIPREL BI-FORT,

- inā ma mua, i ka wā e lawe ai i nā inhibitor ACE ʻē aʻe a i lalo paha nā kūlana ʻē aʻe, ʻo ʻoe a me kekahi o kou ʻohana paha i hōʻike i nā hōʻailona e like me ka wheezing, ka ʻāʻī ʻana o ka maka a i ʻole ʻōlelo, ʻeha loa, a i ʻole he profash skin rash (angiotherapy)

- inā he maʻi koʻikoʻi ka lolo a he encephalopathy hepatic (maʻi pūlohi degenerative),

- inā ua he hewa koʻikoʻi kou hana a i ʻole ʻoe e hele ana i ka dialysis,

- inā he haʻahaʻa loa a kiʻekiʻe paha kou pae kōmela.

- inā ua kānalua ka luhi decompensated ka puʻuwai olakino (ʻoi ka paʻakai paʻakai, pōkole o ka hanu)

- inā he manawa ʻānō ʻoe a ʻo ka makahiki gestational i ʻoi aku o 3 mau mahina (ʻoi aku ka maikaʻi o ka haʻalele ʻana.) NOLIPRELA B-FORT i ka wā mua o ka wā hāpai - ʻike ʻia "ʻO ka ʻae a me ka lactation"),

- ina oe he pakanu.

E kamaʻilio me kāu kauka ma mua o ka lawe ʻana iā NOLIPREL BI-FORTE inā pili kēia o ʻoe iā ʻoe:

inā ʻoe e hoʻopilikia i ka stenosis aortic (kaʻuʻuku ʻana i ka moku koko nui e hele mai ana mai ka puʻuwai), hypertrophic cardiomyopathy (maʻi ʻuhane puʻuwai), a i ʻole stenosis aroteʻi (nāʻuʻina o ka lāʻau e hoʻokahe i ke koko i nā keiki), inā ʻoe e hōʻeha i kekahi maʻi ʻeha, inā ʻoe e hōʻeha i ka hana o ke akeʻalā.

inā ʻoe e ʻeha mai i ka maʻi vascular collagen (maʻi ʻula) e like me ka systemus lupus erythematosus a i ʻole scleroderma.

inā ʻoe e hoʻopilikia ʻia ma ka atherosclerosis (ʻo ka hoʻopaʻapaʻa ʻana i nā paia o nā arela).

inā ʻoe e hoʻomau i ka hyperparathyroidism (hoʻonui i ka hana parathyroid),

ina oe e eha mai i ka gout.

inā ʻoe i ka maʻi maʻi

inā aia ʻoe i ka papa paʻakai haʻahaʻa, a ke ʻole ʻoe e lawe nei i nā paʻakai paʻakai ʻo ia nō ka paʻakai

Inā ʻoe e lawe ana i ka lithium a i ʻole ka potassium-sparing diuretics (spironolactone, triamteren), me ʻoe e lawe ʻole iā lākou i ka manawa like me NOLIPREL BI-FORT (e nānā i "lawe i nā lāʻau lapaʻau".

Pono ʻoe e hoʻomaʻamaʻa i kāu kauka inā manaʻo ʻoe he wahine hāpai. (a i ʻole ka hoʻolālā ʻanahapai). ^ E Ha yM. ʻAʻole ia e kauoha ʻia e lawe i ka NOLIPREL BI-FORT i nā wā mua o ka wā hāpai. ʻAʻole pono e lawe ʻia ka lāʻau pono no nā manawa lōʻihi ma mua o 3 mau mahina, ʻoiai hiki i kēia ke hōʻeha koʻikoʻi i ke olakino o ke keiki (e nānā i "Pregnancy and lactation").

Ke lawe nei ʻoe i NOLIPREL BI-FORT, pono nō ʻoe e hoʻomaopopo i kāu kauka a me nā limahana olakino e pili ana i kēia aʻe:

inā he anesthesia a ʻoi paha ka hoʻokele nui ʻana,

inā ua loaʻa iā ʻoe i ka mākia a nānā ʻole paha, a inā ua pau kou kino,

inā ʻoe e hoʻokomo i ka apheresis o LDL (ka hemo ʻana i ka kolamu ma ke koko),

inā he maʻa ʻoe i ka desensitization, a laila e hōʻemi i nā hopena kūloko i nā bee a i ʻole i ke pala.

inā ke komo nei ʻoe i kahi nānā olakino e koi ai i ka hoʻokele ʻana o ka ʻenehana radiopaque iodine (he ʻano e hiki ai iā ʻoe ke nānā i nā ʻāpana o loko, e like me nā ʻōpū a me nā ʻōpū, e hoʻohana ana i nā x-ray).

Pono e ʻike nā mea pākolo ke ʻike iā NOLIPREL BI-FORTE kekahi mea ikaika (indapamide), hiki ke hāʻawi aku i ka hopena kūpono i ka wā e lawe ana i ka mana doping.

ʻAʻole pono nā palapala o NOLIPREL BI-FORT i nā keiki.

ʻŌpū a me ka lactation

E ʻōlelo aku i kāu kauka a i ʻole ia mea lapaʻau ma mua o ka lawe ʻana i kekahi lāʻau lapaʻau.

Pono ʻoe e paipai i kāu kauka inā ua noʻonoʻo ʻoe he maʻa ʻoe (a i ʻole ka hoʻolālāhapai).

Pono ke kauka e kuhikuhi iā ʻoe e ho'ōki i ka lawe ʻana iā NOLIPREL BI-FORTE ma mua o ka hāpai ʻana a i ʻole ʻoiai i ka hōʻoia ʻana o ka hāpai ʻana, a e kuhikuhi hou i kekahi lāʻau lapaʻau ma mua o NOLIPREL BI-FORT. ʻAʻole ia e kauoha ʻia e lawe i ka NOLIPREL BI-FORT i nā wā mua o ka wā hāpai. ʻAʻole pono ka lālama e lawe i ka lāʻau no nā manawa he lōʻihi ma mua o 3 mau mahina, no ka mea hiki i kēia ke hōʻeha kino i ke olakino o ke keiki.

Inā ʻoe e ʻokiʻoki a hoʻolālā paha i ka umauma, e hoʻomaopopo i kāu kauka. N contipicated ʻo NOLIPREL BI-FORTE ma nā makuahine hānai. Hiki paha i kāu kauka ke hoʻonohonoho iā ʻoe i kahi ʻano ʻē aʻe inā makemake ʻoe e hoʻouluulu, ʻoiai inā he pēpē hou a hānau ʻia paha ma mua o ka lā kūpono.

E kamaʻilio koke me kāu kauka.

ʻ a me ke kākele

Ke lawe nei iā NOLIPREL BI-FORT, e hoʻomau mau i nā ʻōlelo a ke kauka. Inā kānalua ka pololei o ka lāʻau lapaʻau, pono ʻoe e kamaʻilio i kāu kauka a i ʻole ka mea lapaʻau. ʻO ka pākaukau maʻamau ka papa pākahi i kēlā me kēia lā: ʻoi aku ka maikaʻi ma ke kau ʻana i nā papa i ke kakahiaka, ma mua o ka papaʻaina. E hoʻopulu i ka papa papa me kahi ipu wai.

Loaʻa ka hopena

E like me nā lāʻau lapaʻau ʻē aʻe, ʻo NOLIPREL BI-FORTE, ʻoiai ʻaʻole ma ka maʻi āpau, hiki i nā hopena hopena.

E ho'ōki i ka lawe ʻana i kēia lāʻau lapaʻau a hoʻopili aku i kāu kauka inā loaʻa iā ʻoe kekahi o ia ʻano mea:

ua ihu kou alo, mau lehelehe, ka waha, a i ʻole ka ʻūlū, ua pilikia ʻoe i ka hanu, ua ʻāʻā loa ʻoe a i ʻole ka palupalu, he ʻano wikiwiki a i ʻole ʻano kuhi ʻoe.

Loaʻa paha nā hopena ʻaoʻao (i ka hoʻohaʻahaʻa ʻana i ka ʻike o ka neʻe):

Kūpono (liʻiliʻi ma mua o 1 i ka 10, akā ʻoi aku ka nui o ka 1 ma ka 100 o nā mea maʻi): ka ʻeha, ka dizz, ka vertigo, ka ʻula a me ka hoʻowalewale, ʻike maka, tinnitus, lightheadedness ma muli o ke kahe nui o ke koko, ka pipi, ka pōkole o ka hanu, nā hana hōʻeha (nausea , ka luaʻi, ka ʻōpū o ka ʻōpū, nā ʻeha hanu, maloʻo, dyspepsia a i ʻole ka hoʻowalewale ʻana, ka ʻeha ʻana, ka constipation), nā hopena ʻakano (e like me ka ʻāʻī i ka ʻāʻī, Kaʻe), nā ʻeha o ka naʻau, ʻeha nā ʻeha.

Kāhea (ʻaʻole hoʻi ma mua o 1 i ka 100, akā ʻoi aku ka nui o ka 1 ma ka maʻi 1000): ke kuapo ʻana, ke kuapo ʻana, hiamoe ʻole, bronchospasms (ʻāʻī ka pahu, ʻōezing-ʻōpū: a me ka pōkole o ka hanu), angioedema (nā hōʻailona e like me ka ʻoi a hoʻopaʻi paha o ka maka a me ka alelo) , urticaria, purpura (ʻulaʻula i ka ʻili), nā pilikia o ke keiki, ka hemahema, hoʻonui ʻia.

Kino loa (emi iho ma mua o 1 ma kahi o nā poʻe maʻi 10,000): hilahila, nā maʻi cardiovascular (hōʻeha o ka puʻuwai, nā puʻuwai naʻau), eosinophilic pneumonia (he ʻano ʻano o ka maʻi pīpī), rhinitis (hōʻeha o ka ihu a i ka ihu ranole), nā hopena kino ʻeha e like me multiforme erythema. Inā ʻoe e hōʻeha i kahi systemus lupus erythematosus (he ʻano o ka maʻi collagen-vascular), a laila hiki paha ka maʻi. Aia nā hōʻike no nā hihia o nā hoʻonaninani kiʻi (hoʻololi i ke ʻano, ke ʻano o ka ʻili) ma hope o ka hoʻolaha ʻana i ka lā a i nā hihiu UVA artifical.

Hiki i nā ʻeha i loko o ke koko, nā ʻōpū, nā ate, ka pancreas a i ʻole ka loli i nā ʻāpana ʻana o nā kāpili (nā ho'āʻo koko) e hiki mai paha. Hiki i kāu kauka ke kuhikuhi i kahi hoʻokolokolo koko e nānā i kou kūlana.

I ka hihia o ka palaleka o ka ate (maʻi o ke aniani) ka hoʻomaka ʻana o ka hepatic encephalopathy (degenerative brain disease) hiki.

Inā hele a koʻikoʻi nā hopena ʻaoʻao a inā e nānā ʻoe i nā hopena i makemake ʻole ʻia ʻaʻole i kākau inoa ʻia ma kēia lāpiki, e haʻi aku i kāu kauka a i ʻole ka mea lapaʻau.

Hoʻopili pū me nā lāʻau ʻē aʻe

E haʻi mau i kāu kauka a i ʻole kekahi mea lapaʻau āu e hoʻohana ai i nā lāʻau e lawe nei a i ʻole ua lawe nei ʻoe, ʻoiai ʻo ia nā mea lapaʻau maʻamau.

Kāohi i ka hoʻohana ʻana o NOLIPREL BI-FORTE me kēia mau lāʻau lapaʻau:

- lithium (i hana ʻia e mālama pōpilikia),

- diuretics pākelēmi-sparing (spironolactone, triamteren), paʻakai pālolo.

Ma ka hoʻohana ʻana o nā lāʻau ʻē aʻe e pili paha i ka mālama ʻana o NOLIPREL B-FORT. E makaʻala e ʻike i kāu kauka inā ʻoe e lawe nei i kēia mau lāʻau lapaʻau e like me ka mea nui loa ʻoe e makaʻala i ka wā e lawe ai iā lākou:

- nā lāʻau lapaʻau i hoʻohana ʻia i ka mālama ʻana i ka maʻi hypertension,

- procainamide (no ka mālama ʻana i ka ritika puʻuwai o ke kino),

- allopurinol (no ka mālama ʻana i ka gout),

- terfenadine a i ʻole astemizole (antihistamines no ka mālamaʻana i ka mauʻu homa a i ʻole nā ​​maʻi kūwaho),

- nā corticosteroids, kahi mea e hoʻohana ai e mālama i nā kūlana like, e komo pū ana me ka nui o ka maʻi a me ka reheumatoid arthritis,

- nā mea kanu immunosuppressive i hoʻohana ʻia e mālama i ka maʻi autoimmune a i ʻole hoʻi i ka hana hoʻololi e pale ai i ka hōʻole ʻana (e.g.

- nā lāʻau lapaʻau i kauoha ʻia no ka mālama ʻana i ka maʻi maʻi,

- erythromycin intravenously (antibiotika)

- halofantrine (i hana ʻia no ke ʻano o nā maʻi maʻi o ka maʻi maʻi),

- pentamidine (i hoʻohana ʻia no ka mālama ʻana i ka pneumonia).

- vincamine (i hoʻohana ʻia no ka mālamaʻana i ka maʻi cognitive dairment i loko o nā poʻe maʻi maʻi, me ka hoʻomanaʻo ʻana o ka hoʻomanaʻo).

- bepridil (hana i mālama i ka angina pectoris),

- sultoprid (no ka mālama ʻana o ka noʻonoʻo maʻi),

- nā lāʻau lapaʻau i kauoha ʻia no ka mālama ʻana i nā arrhythmias cardiac (e ..g. quinidine, hydroquinidine, disopyramide, amiodarone, sotalol).

- ka Digoxin a i ʻole glycosides cardiac (no ka mālama ʻana i ka maʻi naʻau),

- baclofen (no ka mālama ʻana i ka ʻoi ʻana o ka naʻau, e kū ana ma kekahi mau maʻi, no ka laʻana, me ka sclerosis),

- nā lāʻau maʻi maʻi e like me ka insulin a me ka metformin,

- kalū, me ke kōpona o nā lako hoʻohui,

- ka ulele pōkole (e.g. senna),

- nā mea lapaʻau anti-inflammatory non-steroidal (e.g. ibuprofen) a i nā kaila kiʻekiʻe o nā paʻakai (ma e.g. aspirin),

- ka ʻōpū o ka amphotericin B (no ka mālamaʻana i nā maʻi maʻi)

- nā lāʻau lapaʻau no ka mālamaʻana i nā pilikia noʻonoʻo, e like me ka hopohopo, ka hopohopo, schizophrenia, etc. (no ka laʻana, he tricyclic antidepressants, antipsychotics),

- tetracosactide (no ka mālamaʻana i ka maʻi Crohn).

Nā hiʻohiʻona noi

E hoʻokele i nā kaʻa a me nā kaomi ʻana o nā mīkini,.

ʻAʻole pili iki ka NOLIPREL BI-FORTE i ka kiaʻala, akā ma kekahi mau mea maʻi, ma muli o ke kahe koko haʻahaʻa, ʻike ʻia nā ʻano like ʻole, no ka hoʻohālike, a me ka nāwaliwali. ʻO ka hopena, hiki ke kaomi i ka kaʻa a i ʻole nā ​​mīkini ʻē aʻe i hiki ke kau ʻia.

NOLIPREL BI-FORTE loaʻa ka lactose (pauku kālā. Inā ua haʻi aku ke kauka iā ʻoe e kānalua ʻole ʻoe i kekahi mau meli, a laila e ʻōlelo i kāu kauka ma mua o ka lawe ʻana i kēia lāʻau lapaʻau.

Nā kūlana mālama

E mālama ma mua o ka ʻike a me ka nānā ʻana o nā keiki.

Hoʻopili paʻa i ka ipu paʻa i ka pale ʻana mai ka komo.

Pono e mālama i kēia lāʻau lapaʻau i kahi mahana ʻaʻole iʻoi aku ma mua o 30 ° C.

Mai wehe i ka lāʻau lapaʻau i loko o ka puna wai a i ʻole nāʻauʻau. E noi i kāu lāʻau lapaʻau pehea e loaʻa ai nā lāʻau lapaʻau i pau. Hoʻokumu kēia mau hana i ka pale ʻana i ke kaiapuni.

Lapaʻau lāʻau

Noliprel A Bi-Forte ka hui hui pū ʻia e loaʻa ai kahi angiotensin e hoʻohuli ana i ka enzyme inhibitor (ACE) a me kahi diuretic sulfonamide. Hōʻike ka lāʻau lāʻau i nā waiwai pharmacological e hoʻohui i ka hana o kēlā me kēia o kāna hana. Hoʻohui ʻia nā waiwai antihypertensive ma muli o kā lākou hoʻohui synergism.

ʻO Perindopril kahi mea hoʻoweliweli ACE, ka mea i kapa ʻia. kininase II - exopeptidase i komo i ka hoʻololi ʻana o ka angiotensin I loko o kahi make huena vasoconstrictor angiotensin II, a me ka uhai ʻana o ka bradykinin, he hopena vasodilating e hana ai i ka heptapeptide hana ʻole. Hāʻawi kēia mea waiwai i ka hōʻemi o ka hana ald testosterone, i ka plasma e hoʻonui ai i ka hana ʻo renin e ke kumu o ka manaʻo maikaʻi ʻole, me ka hoʻohana lōʻihi ʻana e hoʻonāwaliwali i ka pale kūloko peripheral maʻamau (OPSS), i hui pū ʻia me ka hopena ma nā moku o nā ʻōpū a me nā ʻōpū. ʻAʻole e hoʻonui kēia mau pilikia i ka ulu ʻana o ka tachycardia a ʻaʻole e alakaʻi i ka hoʻomoʻe a me ka sodium.

Hoʻokuʻu ʻia i ka hōʻemi o ka preload a ma hope o ka ukana, perindopril ka hoʻolaʻa a kākoʻo i ka hana o nā ʻōpū puʻuwai. I ka poʻe maʻi me ka puʻuwai naʻau maʻi (CHF), ma muli o kāna hana (e like me nā hōʻailona hemodynamic), e hoʻopiha ana i ke kaomi ma ka ʻū a me ka hema o ka naʻau o ka puʻuwai, ua emi ka nui o ka puʻuwai, hoʻonui ʻia i ka cardiac a me ka indexation cardiac, a hoʻonui ʻia ke kaila koko peripheral.

ʻO Indapamide kahi hui sulfonamide a hōʻike i nā waiwai lapaʻau e like me nā poʻe o ka diuret thiazide. Ma ka hoʻokaʻawale ʻana i ka sodium reabsorption i ka māhele cortical o ka mela Henle, hāʻawi ka waiwai i ka hoʻonui ʻia ʻana e nā ʻōpū o ka sodium a me nā klorinine, a me ka liʻiliʻi o ka paʻakai - magnesium a me nā paʻakai pālolo, e hana ana i ka hoʻonui ʻia o ka urine a hoʻemi ʻia i ke koko.

Noliprel A Bi-Forte hōʻike i kahi hopena hypotensive hilinaʻi i luna o ka pakanaleka diastolic a me ka systolic, ma ke kūpaʻa a me ka wahaheʻe. Hoʻomaopopo ka hopena antihypertensive o ka lāʻau no 24 mau hola. ʻOi aku ka liʻiliʻi ma mua o hoʻokahi mau mahina ma hope o ka hoʻomaka ʻana o ka papa, ʻike ʻia kahi hopena wai paʻa, kahi i ʻike ʻole ʻia ai ka hopena o ka tachyphylaxis. ʻO ka hoʻopau ʻana i nā lāʻau ke alakaʻi ʻaʻole i ka haʻalele. E kōkua ana ka ʻoihana antihypertensive e hōʻemi i ka pae o ka hypertrophy ventricular hema (GTL), e hoʻomaikaʻi i ka elasticity o nā ʻalihi, hōʻemi i ka OPSS, ʻaʻole i hoʻopili i ka hoʻololi ʻana o nā lipids - triglycerides, ka nui kolesterol, kolamu, haʻahaʻa a me nā kiʻekiʻe lipoproteins kiʻekiʻe (LDL a me HDL).

Ua hoʻohālikelike ʻia ka hopena o ka hoʻohana pū ʻana o perindopril a me indapamide ma GTL i ka hoʻohālikelike ʻia me enalapril. I ka poʻe maʻi me ka hypertension arterial a me GTL, ka mea i lawe perindopril erbumin i loko o kahi wai o 2 mg (e pili ana i ka perindopril arginine i ka nui o 2.5 mg) + indapamide i loko o kahi inika o 0.625 mg / enalapril i loko o kahi inika o 10 mg hoʻokahi i ka lā, ma hope o ka hoʻonui ʻana i ka hapa o perindopril erbumin 8 mg (e pili ana i ka perindopril arginine ma ka nui o 10 mg) + indapamide - a hiki i ka 2.5 mg / enalapril - a hiki i ka 40 mg, me ka nui o ka lawelawe ʻana i ka hui perindopril / indapamide inā i hoʻohālikelike ʻia me ka hui enalapril, he nui ka kahe nui o ka index ma ka ventricular mass e nānā ʻia ( LVMI). Ua ʻike ʻia ka hopena koʻikoʻi ma LVMI i ka wā e hoʻohana ai ka perindopril erbumin 8 mg + indapamide 2.5 mg.

Ua ʻike ʻia kekahi hopena antihypertensive ikaika i ka wā i hui pū ʻia me ka perindopril a me ka indapamide hoʻohālikelike ʻia me enalapril.

ʻO ka hana o ka perindopril i ʻike ʻia i ka mālama ʻia ʻana o ka hypertension arterial o kekahi hōʻeha, ʻelua me ka hana haʻahaʻa a me ka hana renin plasma. ʻO ka hopena antihypertensive loa e nānā i kēia mau hola 4-6 ma hope o ka lawelawe waha a hoʻomau i nā mea e ʻoi aku 24 mau hola. Ma hope o kēia manawa, ʻike ʻia kahi kiʻekiʻe (e pili ana i 80%) o ke koena ACE inhibition.

ʻO ka hoʻohana pinepineʻana o ka diuret thiazide i alakaʻi i ka hoʻonui nui o ka hopena antihypertensive. Eia kekahi, ʻo ka hui pū ʻana o kahi inhibce ACE a me kahi diuretic thiazide e kōkua i ka hōʻemi i ka hopena o ka hypokalemia me ka hoʻohana pono ʻana o ka diuretics.

ʻO ka pū hui ʻana o kahi ACE inhibitor a me kahi angiotensin II receptor antagonist (ARA II) pālua pālua o ka renin-angiotensin-aldosterone system (RAAS) ʻaʻole i ʻōlelo ʻia no nā mea maʻi me ka nephropathy maʻi maʻi. Ua hiki kēia hopena i ka wā kau mau maʻi ma muli o nā maʻi i loaʻa i ka mōʻaukala o ka maʻi cardiovascular a i ʻole cerebrovascular maʻi, a i ʻole type 2 diabetes mellitus me kahi lesion i hōʻoia ʻia o ka hui, a me ka mea maʻi me ka maʻi type type 2. ʻano a me ka nephropathy diabetes. Wahi a nā hopena o nā noiʻi i nā poʻe maʻi e loaʻa ana i kēia hōʻuluʻulu hui, ʻaʻohe hopena maikaʻi i ka hoʻomohala ʻana i ka renal a me / a me nā hanana cardiovascular a me nā uku make. Eia kekahi, ua hoʻoweliweli ʻia ka hoʻoweliweli o ka hyperkalemia, hypotension arterial a me / a me ke kūleʻa ʻana paha o ka renal i kēia hihia ke hoʻohālikelike ʻia me kahi hui o nā mea maʻi e loaʻa ana i ka monotherapy.

Hoʻomaopopo ka hopena antihypertensive o ka indapamide i ka wā e mālama ai me kēia lāʻau lapaʻau i nā peki e hāʻawi ai i ka hopena diuretic liʻiliʻi. ʻO kēia waiwai o ka mea hana e pono ai ka mea e hoʻonui i ka elasticity o nā hua uila nui a me ka hoʻohaʻahaʻa i OPSS. Hoʻolaha ʻo Indapamide i ka GTL, ʻaʻole i pili i ka lipids koko (LDL, HDL, ka nui o ka kolamu, triglycerides) a me ka metabolism hōʻemi a hiki i mua o ka maʻi maʻi.

Perindopril

Ke lawe waha ʻia, lawe koke ʻia ka perindopril. Ka hoʻokūkū nui o ka waiwai (C_max) i ka pili koko ke nānā ʻia 1 mau hola ma hope o ka hoʻokō ʻana. ʻAʻole hōʻike ʻia ka lāʻau lapaʻau e ka hana pharmacological. Ka hapalua ola (T_1/2) 1 hola i ka manawa. Ma kahi o 27% o ka kūlohelohe o ka perindopril aia i ke kahe koko i loko o ke ʻano o kāna metabolite ikaika, perindoprilat. Ma ka hana o ka biotransformation o ka hana ikaika, ka hoʻohui i ka perindoprilat, ua hoʻokumu ʻia nā 5 mau māmehana hou ʻole. Ma hope o ka hoʻoponopono waha ma ka koko plasma C_max ua hoʻokele ʻia ka perindoprilat ma hope o nā hola 3-4, ua hoʻolōʻihi ka meaʻai i ka hoʻololi i ka perindopril i perindoprilat, no laila e hoʻopilikia ai i ka bioavailability o ka lāʻau.

Ua hoʻokumu ʻia ka laina linear o ka pae o perindopril i plasma i loko o kāna momona. Ka Hoʻolaha Mahele (V_{e d}) no ke kiko o ka perindoprilat he 0.2 l / kg. Me nā protein o ka plasma, ʻoi loa me ACE, perindoprilat (ma muli o ke kao ana) e hoʻopaʻa i ka mea e pili ana i 20%.

ʻO ka metabolite hoʻoikaika e hoʻopili ʻia e nā pōpoki mai ke kino, e hoʻohana pono ai ʻo T_1/2 ʻoi ʻia ka hapa liʻiliʻi ma kahi o 17 mau hola, ua loaʻa ke kūlana kūlehu ma loko o 4 mau lā.

Ma ke alo o ka puʻuwai a me nā hina, a me ka poʻe maʻi ma o nā mea maʻi, ua emi iho ka hōʻike o ka perindoprilat. ʻO ka wehe o nā Dialysis o ka waiwai he 70 ml / min.

ʻO ka mea hana kūpono e wikiwiki a holo a i lalo mai o ka gastrointestinal tract (GIT). 1 hola ma hope o ka lawelawe waha, ua loaʻa ʻo C_max indapamide i loko o ke koko koko. Me ka hoʻohana hou ʻana, ʻaʻohe hōʻiliʻili o ka waiwai. ʻO ke kamaʻilio me nā protein plasma he 79%, T_1/2 ʻokoʻa i ka pae mai 14 a 24 mau hola (he awelika o 18 mau hola).

Kuhi ʻia ka Indapamide e nā keiki (ma kahi o 70% o ka nui i lawe ʻia) a me ke ʻano o nā metabolites kūleʻa ma o nā ʻōpū (kokoke i 22%).

ʻAʻole loli i nā ʻōkola pharmacokinetic i nā maʻi me ka maikaʻi ʻole.

Nā ʻōlelo kikoʻī

I loko o ka manawa o ka hopena, pono e ʻike ʻia nā hōʻailona lapaʻau o ka hōʻemi a me ka hoʻēmi ʻana i ka pae plasma o ka electrolytes e pono ai, me ka ʻōpū ʻana a me / a i ʻole e puhaka, no ka mea, i ka hopena o ka hyponatremia mua e loaʻa ka hopena o ka ulu ʻana o ka ulu ʻana o ka hypotension arterial. I ia mau pilikia, pono ka nānā ʻana o ka neʻe ʻana o ka paʻa o nā electrolytes i ka plasma koko.

Inā ʻike ʻia ka hypotension arterial, iv ka hoʻokō ʻana i kahi hopena o ka sodium chloride 0.9%.

ʻAʻole he contraindication no ka transter arterial hypotension no ka hoʻomaʻamaʻa hou aku me Noliprel A Bi-Fort. Me ka hoʻohaʻahaʻa ʻana o ke koko a me ka bcc, hiki iā ʻoe ke hoʻomau i ka hoʻohana ʻana i ka lāʻau lapaʻau ma nā haʻahaʻa haʻahaʻa, a i ʻole e hoʻohana ai i kekahi o nā mea hana wale nō.

E pale aku i ke ʻano o ka mālama ʻana, ua hoʻopaʻa ʻia nā hihia o nā lēʻeha maʻi maʻamau, i kekahi manawa ke kūleʻa nei i ka maʻi antibiotic intensive. Ke hoʻohana nei i perindopril i kēlā mau maʻi, pono ia i nā manawa maʻamau e nānā i ka nui o nā leukocytes i ke koko. Pono ka poʻe maʻi e hoʻomaopopo i kā lākou kauka i kekahi mau hōʻailona o nā maʻi maʻi (e komo ana i ke kuni a me ka ʻehaʻeha).

I ka wā o ka mālama ʻana me Noliprel A Bi-Forte, ua loaʻa nā hanana hōʻemi o ka ulu ʻana o ka angioedema o ka huaʻōlelo, nā lehelehe, nā lipole leo a / a i ʻole larynx, alo, a me nā limu. Hiki i kēia mau ʻōuli i kekahi manawa i ka wā o ka lapaʻau. Ke hele mai nei nā hōʻailona o ka edion angioneurotic, pono e hoʻokaʻawale i ka lāʻau lapaʻau a nānā pono ʻia ke ʻano o ka mea maʻi a hiki i ka wā e hoʻopau ʻia ai nā hōʻailona o kēia lesion. Inā ua pālahalaha aku ka palaka i ka maka a me nā lehelehe, a laila ma ka hapanui o ka wā e hele aku ai nā hōʻailona ma luna o lākou, ʻoiai inā pono, hiki ke kuhikuhi pū ʻia nā antihistamines. ʻO ka edion Angioneurotic, i hele pū me ka laryngeal edema, hiki i ka make. ʻO ka puhi ʻana i nā kuʻi leo, ʻōlelo a i ʻole larynx e hoʻonui ai i ke kuahiwi. Me ka hoʻomohala ʻana o kēia mau ʻōuli, ua hōʻike ʻia e hoʻoiho koke i ka epinephrine (adrenaline) ma kahi niniki o 1: 1000 (0.3-0.5 ml) a i ʻole hana i nā hana e hōʻoia ai ka hoʻomakehū ʻana.

Aia nā mea pili i kahi kūlana kiʻekiʻe o ka angioedema i nā mea maʻi o ka lāhui Negroid.

Ma nā hihia nui ʻole, i ka wā e mālama ai me ka inhibitor ACE, ʻike ʻia ka hoʻomohala ʻana o ka angioedema o ka ʻōpū, i hele pū ʻia me ka ʻeha ma loko o ka ʻōpū (me a ʻole a i ʻole ka luaʻi / nausea), i kekahi manawa me ka ʻike maʻamau o C1 esterase a me ka hele ʻole ma mua o ka angioedema o ka maka. Hoʻokumu ʻia ka hōʻike ʻana o kēia hopena ʻino e ka compect tomography (CT) nānā o ka ʻōpū o ka ʻōpū, ʻĀpana (ultrasound) a i ʻole ka wā hana. Hoʻomaopopo nā hōʻailona o ka lesion ma hope o ka hoʻokuʻu ʻana o nā pale o ACE.

I nā maʻi me nā maʻi pālolo, i ka wā e lawe ai i ka desensitization, pono e hoʻohana ʻia nā mea hoʻokele ACE me ka mālama nui loa. ʻO ka poʻe maʻi e loaʻa ana i ka immunotherapy me nā mākaukau e pili ana i ka iniseti manuʻai hymenopteran (me nā piʻolima a me nā wasps) pono e pale i ka hoʻohana ʻana o ka inhibce ACE, no ka mea e hoʻonui ai kēia i ka hoʻomohala ʻana o ka hoʻomau ʻana i ka manawa anaphylactic hoʻoweliweli. Eia naʻe, hiki ke pale ʻia kēia mau hopena ma ka hoʻokaʻawale iki ʻana i nā ACE inhibitors ma kahi o 24 mau hola ma mua o ke kaʻina hana desensitization.

I ka heleʻana o ka hypertension arterial a me ka maʻi ʻōpū coronary i ka wā o ka hōʻola, ʻaʻole pono ka mea maʻi e ʻoki me ka hoʻohana ʻana i nā beta-blockers.

ʻO Perindopril, e like me ko ACE inhibitors, hōʻike i ka hopena antihypertensive nāwaliwali i nā mea maʻi o ka lāhui Negroid inā i hoʻohālikelike ʻia me nā ʻelele o nā lāhui ʻē aʻe. Manaʻo ʻia kēia ʻokoʻa e pili pono i ka hana o ka hana renin haʻahaʻa pinepine i ka poʻe maʻi o kēia lāhui me ka haʻi hypertension.

E kū'ē i ke kumu o ka mālama ʻana me ka diuretics thiazide, aia kahi mau mea e pili ana i nā hoʻonaninani photosensitivity, ka hoʻomohala ʻana e pono ai ka lāʻau e hoʻokuʻu. Inā hoʻomau ʻoe i ka hoʻomehana diuretic, ʻoi aku ia e pale i ka ʻili i ka ʻike ʻana i ka māmā a me nā ʻāpana ultraviolet ʻano.

Hiki i Indapamide ke hoʻonāukiuki i kahi hopena maikaʻi i ka mea hoʻokūkū i ka wā doping.

Hoʻokomo i ka hiki ke lawe i nā kaʻa a me nā mīkini paʻakikī

ʻO nā mea ikaika a Noliprel A Bi-Forte, ʻaʻole alakaʻi i nā haunaele i ka hopena psychomotor. Akā e pono hoʻi i ka noʻonoʻo ʻana i kekahi mau mea maʻi e ulu ai ka hopena o ka hoʻonaninani i ke ʻano o ka hoʻemi ʻana o ke koko, ʻoi aku ka hoʻomaka o ka hoʻomaʻamaʻa ʻana a me ka hoʻohana like ʻole me nā lāʻau antihypertensive. I kēia hihia, hiki i ka hiki ke hoʻokele i nā kaʻa a hana paha me nā lako ʻē aʻe paha e pilikia.

ʻŌpū a me ka lactation

Pono nā wahine hāpai a me nā wahine e hoʻolālā ana i kahi hāpai ʻana e lawe iā Noliprel A Bi-Forte. ʻO ka hoʻopaʻa ʻia ʻana o nā haʻawina hoʻokō ʻana me nā ACE inhibitors i nā wahine hāpai ʻaʻole i hana. Loaʻa nā ʻikepili e pili ana i ka hopena o ka lāʻau ma ka trimester mua o ka hānau ʻana e hōʻike ana i ka haʻalele ʻana o nā hemahema hoʻomohala i pili i ka lāʻau me ka fetotoxicity. ʻOiai ʻo kēia, hoʻonui ʻia i kahi hoʻoweliweli o ka maʻi hoʻomohala ʻana i ka maʻi hānai e hiki ʻole ke kāohi ʻia i ka wā e lawe aku ai i nā pale o ACE.

Inā hele mai ka hapai i ka wā o ka lapaʻau me ka lāʻau lapaʻau, pono e kāpae i ka hoʻohana ʻana iā Noliprel A Bi-Forte a kuhikuhi i kahi lāʻau antihypertensive hou me nā lāʻau lapaʻau i ʻae ʻia no ka hoʻohana ʻana i ka wā hāpai. I loko o ka II - III trimesters, me ka lōʻihi o ka hōʻike ʻana i nā mea paʻa o ka ACE e pili ana i ka ʻōpū, ka nui o ka hōʻeha ʻana i nā maʻi hoʻomohala, e like me ka oligohamoamnion, ka hana ʻole o ka pūlea, a i ʻole e hōoki i ka ossification o nā iwi ʻōpala, e hoʻonui ai. Hiki i kahi pēpē hou ke loaʻa i ka hypotension arterial, renal failed, hyperkalemia.

Inā loaʻa ka wahine i ka mālama ʻana me ka ACE inhibitors i loko o ka II - III trimesters o ka hāpai ʻana, e hana ʻia kahi ultrasound o ka pūpū e loiloi i ka hana o kaʻeha a me ke ʻano o ka ʻihi. ʻO nā pēpē i lawe i nā makuahine i kēia mau lāʻau i ka wā hāpai e pono ke mālama pono i ka lāʻau lapaʻau no ka ʻike pono ʻana i ka manawa a me ka hoʻoponopono ʻana i ka hypotension arterial hiki.

I ke kolu o ka wā ʻekolu o ka hāpai ʻana, e hoʻolōʻihi ʻia ka lāʻau lōʻihi me ka diuret thiazide hiki i ka hypovolemia maternal a me ka hoʻolilo ʻana i ke kahe koko uteroplacental, ka mea i hoʻopuka i ka ischemia fetoplacental a me ka hoʻoulu ʻana i ka maʻi fetal. I ka wā e mālama ai me ka diuretics, ma hope o ka hānau ʻana, i kekahi mau hihia, ua loaʻa nā thrombocytopenia a me hypoglycemia.

Hoʻohana ʻia ka hoʻohana ʻana o Noliprel A Bi-Forte i ka wā mālama ʻana i ka umauma. ʻAʻole i ʻike ʻia inā komo ka perindopril i ka waiū umauma, akā ua hoʻokū ʻia ua hoʻopili ʻia ka indapamide i loko o ka waiū kanaka a hiki ke alakaʻi i kahi pēpē hou i ka hoʻomohala ʻana o ka hypokalemia, ka lāʻau nukleen a me hypersensitivity i ka wai o sulfonamide. ʻO ka lawe ʻana i ka diuret thiazide hiki ke hoʻonāukiuki i ka ʻoihana o ka lactation a i ʻole ka hoʻemi ʻana i ka nui o ka waiū umauma.

Me ka hana pūnāwai paʻa ʻole

ʻO nā mea maʻi me CC ≥60 ml / min i ka wā hana e pono ai ka mālama pinepine ʻana i ka pae o ka paʻū o ka pāhana a me ka creatinine i loko o ke koko koko.

Ma ke alo o ka hoʻohuli i ka hopena o ka renal kino (CC ma lalo o 60 ml / mau min), ua contraindicated ʻo Noliprel A Bi-Forte. I kekahi mau mea maʻi me ka hypertension arterial me nā hōʻailona ʻole o mua o ka hana ʻole i hana ʻia, hana ka hopena o ka laboratorium e hōʻike i nā hōʻailona o ka hana ʻole. I kēlā mau hihia, pono e hoʻoneʻe ʻia ka lāʻau lapaʻau. Hiki iā ʻoe ke hoʻomau i ka mālama ʻana me nā haʻahaʻa liʻiliʻi o ka hui ʻana o nā mea ikaika, a i ʻole ka hoʻohana ʻana i kekahi o nā lāʻau lapaʻau. I ka poʻe maʻi ma kēia pūʻulu pilikia ʻoi, pono ke nānā aku ka mākia o ka serum a me nā paʻakai potoma 2 mau pule ma hope o ka hoʻomaka ʻana o ka lawe ʻana iā Noliprel A Be-Forte a ma hope iho i kēlā me kēia 2 mau mahina. ʻO ka hapa nui, hana ʻole ʻia ka hopena i loko o nā mea maʻi me ka hana mua o ka hana o ka pēpē (me ka stenosis renal) a i ʻole ka hopena naʻau.

Me ka hana pūpū hemahema

I mua o kahi hōʻeha kino o ka nui ole o ka puhaka, ua contraindicated ka hoʻohana ʻana o Noliprel A Bi-Forte. ʻO nā maʻi me ka maʻi hepatic moderate e pono pono e hoʻoponopono i ka pāpale.

I kekahi mau hihia, i ka wā o ka hoʻohana ʻana o nā inhibitor ACE, ua ʻike ʻia ke ʻano o nā jaundice cholestatic. E pale aku i ke kua o ka holomua o kēia hopena, hiki i ka hiki ke hoʻomohala ʻia o ka necrosis ati fulminant, i kekahi manawa me ka hopena momona. ʻAʻole maopopo. Inā i ka manawa o ka lawe ʻana iā Noliprel A jaundice Bi-Forte i nui a i ʻole ka nui o ka hana ʻana o nā enzyme o ka ate, pono e hoʻokuʻu ʻia a me ke ʻano e ʻike koke ʻia i kahi kauka.

ʻO ka lawe ʻana i ka diuret thiazide / like-thiazide me ka lawelawe kōpaʻa i loaʻa ʻole ke hiki i ka hoʻomohala ʻana i ka hepatic encephalopathy. I kēia hihia, pono e pani koke i ka mālama ʻana me Noliprel A Bi-Fort.

Hoʻohana i ka wā kahiko

Ma mua o ka hoʻomaʻamaʻa ʻana, pono e maʻi nā poʻe maʻi e loiloi i ka hana hana o nā aʻalolo a me ka plasma o ka pāhana o ka pāhana i loko o ke koko. I kēia māhele o nā mea maʻi, pono e hoʻoholo i nā pae o ka protein creatinine i ka noʻonoʻo ʻana i ka makahiki, ka paona o ke kino a me ka wahine. I ka hoʻomakaʻana o ke ala o ka papa no ka poʻeʻelemakule, ua kau ʻia ka nui o ka perindopril e pili ana i ke kiʻekiʻe o ka hoʻemi ʻana o ke koko, ʻoi loa me ka hoʻemi ʻana i ka bcc a me ka nalowale o nā electrolytes. Hāʻawi kēia mau hana i ka pale ʻana ʻana i ke kahe o ke koko.

Hoʻomaopopo ʻia nā mea maʻi a me nā hana o ka lāʻau Noliprel A Bi-Forte e lawe i ka papa 1 i ka manawa i kēlā me kēia lā e like me ka maʻamau.

Hoʻohui nūhou

ʻO nā hui i noi ʻia ʻo Noliprel A Bi-Forte, a me nā mea e lawelawe ana me nā mea waiwai ʻē aʻe:

• Hoʻomake ka lithium: ka hoʻonui ʻana o ka hoʻonui hou ʻana i ka ʻike o ka lithium i loko o ke kaila koko a me nā hopena i ʻole nā ​​mea make i ka wā e hāpai ana i ka inhibitions ACE, hiki i ka hoʻohana hou ʻana o ka thiazide diuretics hiki ke hoʻonui i ka pae o ka plasma o ka lithium a hoʻonui i ka nui o ka hopena o nā mea laʻa, inā pono ke hui pū ʻia, e ʻike pono ʻia ka pae. līpia plasma,
• estramustine: ʻo ka hoʻoweliweli o ka piʻi o ka piʻi o ka hopena o nā hopena ʻokoʻa, ʻoi aku ka angioedema, ke hoʻonui ʻia i ka wā e hui pū me ka perindopril,
• Hoʻomaha pāhau, potoma-sparing diuretics (spironolactone, amiloride, triamteren, eplerenone), mau pā paʻahana pākeke me ka paʻakai ʻai: aia nā paʻakai o ka serum ma loko o nā palena maʻamau, hiki pinepine i ka ulu ʻana nā hyperkalemia - i hui pū ʻia me nā inhibitor ACE, ua lawe ʻia kēia mau lāʻau āpau me ka lāʻau lapaʻau. hiki i ka nui o ka hoʻonui i ka potassium serum a hiki i ka make, me ka hypokalemia paʻa, pono e mālama a mālama ʻia g plasma kūlike o ka pāhare pākaha a me nā helu ECG.

ʻO nā hopena e pili ana i ka hoʻopili ʻana e pono ai ke nānā aku a me ka makaʻala ʻana i ka hoʻohana pono ʻana o Noliprel A Bi-Fort a i ʻole kāna mau mea hana me nā lāʻau lapaʻau e like me kēia:

• baclofen: e hoʻonui pono i ka hopena antihypertensive, pono e mālama ʻia ke koko, a me ka hana o ke keiki, inā pono, pono ʻia ka hoʻoponopono ʻana o nā lāʻau antihypertensive,
• Nā NSAIDs (e pili ana i ka acetylsalicylic acid i loko o nā koina nui o ka 3,000 mg i kēlā me kēia lā, ʻaʻole i koho ʻia ʻo NSAIDs a me COX-2 inhibitors): E emi paha nā hopena antihypertensive inā hui pū ʻia me ka ACE inhibitors, ʻoi aku ka hopena o ka hana renal impaired, e like me ke ʻano o ka hoʻomaʻalike ʻana i ka pilikia renal, a hoʻonui ʻia, a hoʻonui i nā pae pālima serum, ʻo ka mea nui i nā mea maʻi me ka hana mua ʻole o ka hana holi, pono e hoʻihoʻi nā mea maʻi i ka hoʻemi ʻana i nā koena wai a mālama pono iā ia i ka hoʻomaka ʻana o ka hui pū ʻana a ma ke ʻano o kāna papa. ochek,
• ʻO nā maʻi waha hypoglycemic i puka mai i ka sulfonylureas: ka hopena o ka hypoglycemic o kēia mau lāʻau a me ka piʻi ʻana o ka insulin i nā mea maʻi me ka mellitus diabetes ma kahi e lawe ana i kahi ACE inhibitors, he mea maʻamau loa ia no ka hypoglycemia e hele mai ma muli o ka hoʻonui o ka hoʻohaʻahaʻa glucose a hoʻemi i ka koi ʻana o ka insulin, e koi ʻia ka nānā ʻana i ka pae o ka glucose glucose i ka malama mua o keia ahahui,
• antiarrhythmics o ka papa IA (quinidine, disopyramide, gidrohinidin) a me ka papa III (bretylium tosylate, dofetilide, amiodarone, ibutilide), sotalol, benzamides (sultopride, amisulpride, tiapride, sulpiride), neuroleptics (levomepromazine, chlorpromazine, tsiamemazin, trifluoperazine, thioridazine) , butyrophenones (droperidol, haloperidol), pimozide, difemanil methyl sulfate, sparfloxacin, bepridil, halofantrine, cisapride, moxifloxacin, erythromycin (iv), pentamidine, misolastine, vincamine (iv, astad terfad, terfad e hoʻomaka a pirouette type ritme): ka paʻakikī o ka hypokalemia me ka hoʻohana ʻana i ka indapamide, e hoʻomāliʻelele ana, ka mana o ka paila QT, koi pākīpī plasma, a inā pono, hoʻoponopono ʻia o hypokalemia,
• gluco- a me mineralocorticoids (he hopena systemic), amphotericin B (iv), tetracosactide, laxatives e hoʻōla ai i ka ʻōpū o ka ʻōpū (nā ʻaina e hiki ai ke hoʻonāukiuki i hypokalemia): ma muli o ka hopena hoʻohui, ke hui pū me ka indapamide, piʻi ka nui o ka hypokalemia, koi ʻia ka manaʻo ʻana o ka pāhare i ka pīhoihoi, a inā pono pono hoʻi iā ia ke hoʻoponopono ʻana, e koi aku ka poʻe maʻi e loaʻa ana i ka glycosides cardiac me ka mālama pono ʻana, ua ʻōlelo ʻia e hoʻohana i nā laxatives i hōʻeuʻeu ʻole ʻia. iruyut peristalsis,
• glycosides cardiac: hoʻonui ʻia ka hopena o kēia mau lāʻau me ka hypokalemia, no laila, i hui pū ʻia me ka indapamide, pono ke kūleʻa ka pāhare potassium ma loko o ka plasma a me nā ʻōkuhi ECG, pono e hoʻoponopono ʻia ka lāʻau maʻi.
• ʻO nā pilina e koi ana i ka nānā pū me ka hoʻohana pū ʻana o Noliprel A Bi-Fort a i kāna mau mea e koi ana me nā lāʻau lapaʻau / nā mea e hiki mai ana.
• tetracosactide, corticosteroids: nawaliwali ka hopena antihypertensive, ma muli o ka hoʻomau ʻana o nā wai a me nā kaomi sodium ma muli o ke ʻano o nā corticosteroids,
• nā lāʻau antipsychotic (antipsychotics), tricyclic antidepressants: hoʻonui ka hopena antihypertensive a me ka hoʻoweliweli o ka orthostatic hypotension ua hoʻohui ʻia (hopena hoʻohui).
• nā lāʻau lapaʻau antihypertensive aʻai, vasodilators: hoʻonui i ka hopena hypotensive,
• ʻO ARA II inhibitors, aliskiren: ʻoiai ke lawe nei i kēia mau lāʻau me kahi mea hoʻopau ACE, ka ulu ʻana o nā hopena maikaʻi ʻole, e like me hyperkalemia, hypotension arterial, hana hōʻeha o ka hana (me ka hana pūlea o ka papale) ma luna o RAAS, ma muli o kēlā me kēia pālua o ka blockade o RAAS ma o ka hoʻohana hoʻohui ʻana o ka ACE inhibitor me ARA II a i ʻole aliskiren ʻaʻole ia i aʻo ʻia, inā pono kēia hui ʻana, hele i lalo o ka mālama ʻia ʻana o ka lāʻau lapaʻau koʻikoʻi, me ka mālama pinepine ʻana o ka neʻe o ka pāhana i ka plasma, hana like ʻole a me ke koko,
• ʻO ka maʻi thiazide a me ka diuretics loop (ma nā kau palena kiʻekiʻe): ulu ka hypovolemia, i ka wā i hoʻohui ʻia kēia mau lāʻau i ka hoʻōlapa perindopril, nui ka piʻi ʻana o ka hypotension arterial,
• nā lāʻau lapaʻau cytostatic a me ka immunosuppressive, allopurinol, corticosteroids (me ka hoʻohana ʻana i nā ʻōnaehana system), procainamide: hoʻonui ka hopena o ka leukopenia i ka wā e lawe ana i ka pale o ACE.
• hoʻomākaukau no ka anesthesia aoao: hoʻonui ʻia ka hopena antihypertensive inā hui pū me ka perindopril, ke noi ʻia nei ʻoe e hoʻōki i ka lawe ʻana iā Noliprel A Bi-Forte inā hiki i 24 mau hola ma mua o ka hana ma ke ʻano he anesthesia aoao.
• ʻO nā gliptins (sitagliptin, saxagliptin, linagliptin, vildagliptin): e hoʻonui ʻia ka hopena o ka angioedema i ka hui pū ʻana me ACE inhibitors ma muli o ke kaohi o ka hana dipeptidyl peptidase-4 e ka gliptin,
• i hoʻohaʻahaʻa ʻia i loko o nā maʻi antihypertensive:
• Nā hoʻomākaukau gula (iv), me ka sodium aurothiomalate: me ka hoʻohana ʻana o nā inhibitor ACE, hiki ke ulu ʻia nā ʻano nitrate, e like me ka nausea, ka luaʻi, ka hypotension arterial, hyperemia o ka ʻili o ka maka.
• Iodine-nā mea hoʻohālikelike e ʻoi aku ai (ma ka nui o nā inika nui): ka hopena o ka ulu ʻana o ka hana ʻino ʻole a me ka hopena o ka hōʻemi ʻana o ke kino i ka wā e lawe nei i nā lāʻau diuretic, ma mua o kēia hui ʻana, pono ia e hoʻihoʻi i ke kaulike o ka wai.
• metformin: ka hopena o ka lactic acidosis ma muli o ka hana ʻole o ka renal i hana ʻia me ka lawe ʻana i ka diuretics (ʻoi aku ka nui o nā loopbacks) hoʻonui me kahi pae ʻana o ka plasma o 15 mg / l (135 μmol / l) i nā kāne a me 12 mg / l i nā wahine ( 110 usedmol / L) me ka hoʻohana ʻana i ka metformin, ʻaʻole pono e hoʻohana,
• kaleka paʻakai: hoʻomohala ʻia ka hypercalcemia ma ke ʻano o ka hoʻohaʻahaʻa ʻana i ka ʻōpū o ka calcium calcium,
• cyclosporine: hoʻonui i ka ʻike o ka likinine i loko o ka plasma me ka waiho ʻole o nā loli i kona pae, hiki i nā pae maʻamau o ka wai a me ka waiwai sodium.

The analogs of Noliprel A Bi-Fort are Noliprel A, Noliprel A forte, Ko-Perineva, Perindopril-Indapamide Richter, Co-Parnawel, Noliprel, Noliprel forte, Perindid, Perindapam, Perindopril PLUS Indapamide and others.

Nā Hōʻikeʻike e pili ana iā Noliprel A Bi-Fort

Hōʻike nā loea e pili ana iā Noliprel A Bi-Fort i ka nui o nā hihia he maikaʻi. Hoʻomaopopo nā mea maʻi me ka lāʻau antihypertensive hui pū me ka hoʻomaʻamaʻa ʻana i ke kahe o ke koko, hoʻomaikaʻi i ka elasticity o nā paia o nā kīʻaha koko, a me ke kōkua i ka hōʻemi o ka GTL. I nā maʻi me ka maʻi maʻi, ʻaʻole pili ʻo Noliprel A Bi-Forte i ka glucose koko, e like me kekahi o kāna mau analogues. Manaʻo nā kauka he nui kūpono ia no ka mālama ʻana i ka hypotension mua me ka hiki ke hoʻoponopono hou ʻia.

ʻO nā hemahema o ka lāʻau lapaʻau e komo me ka nui o nā contraindications a me nā hopena paha.